Comparing ultrasound and MRI to screen for liver cancer in high-risk people
Part of Cancer, Digestive system clinical trials.
This trial tests how well ultrasound, standard MRI, and special MRI (with a contrast agent) find liver cancer in people at high risk. You may join if you have certain risk factors like hepatitis B or C, heavy alcohol use, fatty liver, or a family history of liver cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have at least one high-risk factor for liver cancer (like hepatitis B/C, heavy alcohol use, fatty liver, or a family history).
- Your aMAP score (a check of your age, sex, and blood tests) is between 60 and 100.
- You haven't had any signs of liver cancer on recent scans (ultrasound, CT, or MRI) in the last 6 months.
- You don't have a history of liver cancer, current liver cancer, or other cancers.
- You are not pregnant or breastfeeding, and your kidneys work well enough (GFR over 50).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study aims to improve how doctors diagnose and treat liver cancer by combining advanced imaging tests and genetic analysis. It may help in choosing the most effective treatment for each person.
This study tests a quicker MRI screening approach for people with cirrhosis to look for liver cancer early. It may help make liver cancer checkups faster and easier while still finding cancers when they are small.
This study compares MRI and ultrasound to see which is better at finding liver cancer early in people with liver cirrhosis. It also looks at body composition and other factors that could lead to worsening liver function.
This trial uses special MRI scans to learn more about liver cancer (hepatocellular carcinoma) before and during treatment with TACE or SIRT. It may help doctors better understand how the tumor responds to therapy.
This trial tests a new type of MRI scan (hyperpolarized 13C-MRI) in people with liver cancer who are already receiving radiation therapy, atezolizumab (an immunotherapy), and bevacizumab (a targeted therapy). The goal is to see if the scan can help doctors better understand how the cancer responds to treatment.
This trial compares two types of scans to see which detects liver cancer better in people at high risk. You would receive either an MRI with contrast or an ultrasound every 6 months to monitor for liver cancer.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.